News

According to the organization, the trip marks the 12th training project in Vietnam for the Flying Eye Hospital, including one virtual project on Cybersight, Orbis's telemedicine platform.

Anthony Wallace, Vice President and General Manager of the US Surgical Business at Bausch + Lomb, discussed the introduction of SeeLuma, a fully digital surgical visualization platform, and more at the 2023 ASCRS annual meeting in San Diego.

Patrick Herde, General Manager of Ophthalmology and Optometry at ModMed, discussed a retrospective on the company's 10-year anniversary 2023 ASCRS annual meeting in San Diego.

Denise M. Visco, MD, discussed her presentation on astigmatism management with a dual-pulse femtosecond laser called ALLY, from Lensar, at the 2023 ASCRS annual meeting in San Diego.

Edward Hu, MD, PhD, discussed his paper on the single surgeon retrospective comparative analysis of 517 eyes of two subgroups of routine cataract surgery at the 2023 ASCRS annual meeting in San Diego.

Zeba Syed, MD, from Wills Eye Hospital discussed their research on corneal swelling and dynamics during corneal collagen crosslinking at the 2023 ASCRS annual meeting in San Diego.

At the American Society of Cataract and Refractive Surgery annual meeting in San Diego, data was presented from the STORM study that demonstrate vision quality to be a major driver of the patient decision to undergo surgery.

According to the company, the announcement represents the first FDA-approved, fixed-combination of tropicamide and phenylephrine for mydriasis.

Sandor Palfi, Commercial Vice President of the Americas at Johnson & Johnson Vision discussed pipeline updates for the company including the ELITA femtosecond platform at the 2023 ASCRS annual meeting in San Diego.

Lowe is the VP, of Commercial Operations at Eyenovia, and discussed the FDA approval of MydCombi for mydriasis at the 2023 ASCRS annual meeting in San Diego.

According to the company, a PDUFA date has been set for December 22, 2023.

Scientists at Medical College of Georgia demonstrated in their animal model of retinopathy of prematurity that the small molecule K604, which is being explored in cancer and Alzheimer’s, can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth

Bharti Nihalani-Gangwani, MD, from the Department of Ophthalmology, Children’s Hospital, and Deborah VanderVeen, MD, from the Department of Ophthalmology, Harvard Medical School, Boston, reported that 29% developed glaucoma in a large infant cohort and the risk factors at the American Society of Cataract and Refractive Surgery annual meeting.

Rob Weinstock, MD from the Eye Institute of West Florida presented on his experience working with the ALLY cataract femtosecond laser cataract system from LENSAR at the 2023 ASCRS annual meeting in San Diego.

Ophthalmology Times© met with Eva Liang at the 2023 ASCRS annual meeting in San Diego where she presented data on outcomes of the Rasch-scaled Catquest-9SF questionnaire before and after implantation of the enVista toric lens.

Jim Mazzo, executive chairman of Neurotech Pharmaceuticals, discussed the company's goal to slow down the progression of MacTel and their recent advancements at the ASCRS annual meeting in San Diego.

Lance Kugler, MD, recapped his presentation and findings on the safety of office-based cataract surgery with the Ophthalmology Times© team at the ASCRS annual meeting in San Diego.

Mark Baum, CEO of Harrow discussed the recent launch of Iheezo and other key updates from the company with the Ophthalmology Times© team at the ASCRS annual meeting in San Diego.

Ophthalmology Times© caught up with Alice Epitropoulos at the 2023 ASCRS annual meeting in San Diego. Among her presentations at the event, she shared data regarding the visual and refractive outcomes of aberration-free monofocal hydrophobic toric IOLs.

Lucie Moore, BSc, in a presentation at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, said the study focused on identifying factors that could put patients at a higher risk for developing dry eye disease.

Ophthalmology Times© spoke with Greg Kunst about Aurion BioTech's 12-month data from their recent Escalón trial 2023 at the ASCRS annual meeting in San Diego.

Alcon presented details from a new study at the American Society of Cataract and Refractive Surgery’s annual meeting taking place in San Diego, California. The investigator-initiated study led by J. Morgan Micheletti, MD, demonstrated that Clareon and Eyhance monofocal IOLs provide similar range of vision, including distance and intermediate visual acuity.

The study, titled “A Clinical Registry Study of Glaucoma Medication Use in Patients with Mild Glaucoma Severity After MIGS,” will be presented Sunday by Michael Mbagwu, MD, at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, California.

Stephen Coleman from Coleman Vision in Albuquerque, New Mexico, spoke with the Ophthalmology Times© team discussed the long-term outcomes with LASIK using the iDesign 2.0 software.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego about the a new FDA clinical trial for a device called StableVisc being launched on the market by Bausch + Lomb.

George Waring IV, MD met with the onsite Ophthalmology Times© team to share data from his presentation on the first in-human results for the OmniVu IOL system.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego where he shared insights from his presentation comparing patient results of the Hydrus stent and the iStent inject W with or without ABiC (or ab-interno canaloplasty).

Erin Powers, Vice President of Global Marketing and Product Strategy for BVI Medical stopped to talk with Ophthalmology Times© at the 2023 ASCRS meeting in San Diego, California to share the latest news from the company.

Ophthalmology Times© spoke with Richard Lewis, CMO of ViaLase at the 2023 ASCRS meeting in San Diego. There he gave out team the details of his presentation for the 2 year follow up of the first in-human study of Femtosecond Laser Image Guided High-Precision Trabeculotomy (FLigHT).

John Berdahl, MD sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his abstract on the Phase 3 trials of iDose TR, versus topical timolol at the ASCRS annual meeting in San Diego.